Coronavirus Studies in Nonhuman Primate Models
This page provides a curated list of coronavirus studies and reviews using nonhuman primate (NHP) models.
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: CureVac AG; Ragon Institute of MGH, MIT and Harvard; Harvard Medical School
Keywords: SARS-CoV-2, mRNA vaccine, immunogenicity and protective efficacy, immune response, primates
Summary of Study: Optimization of non-coding regions can greatly improve the immunogenicity and protective efficacy of a non-modified mRNA SARS-CoV-2 vaccine in macaques. Improved characteristics of CV2CoV, compared with CVnCoV, may translate into increased efficacy in humans, and clinical trials of CV2C0V are planned.
References: doi: 10.1038/s41586-021-04231-6
Contact Info: Susanne Rauch: [email protected]; Daniel Barouch: [email protected]
URL: https://www.nature.com/articles/s41586-021-04231-6
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Scripps Research Institute; MIT; UCSD; Howard Hughes Medican Institute
Keywords: SARS-CoV-2, receptor-binding domain vaccine, structural studies, immune response, primates
Summary of Study: Broadly neutralizing antibodies to an unappreciated site of conservation in the RBD in SARS-related viruses can be readily induced in rhesus macaques because of distinct properties of the naive macaque B cell repertoire that suggest prudence in the use of the macaque model in SARS vaccine evaluation and design.
References: doi: 10.1101/2021.07.05.451222
Contact Info: Ian Wilson: [email protected]; Dennis Burton: [email protected]; Raiees Andrabi: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.07.05.451222v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands
Keywords: SARS-CoV-2, post-acute phase, pulmonary disease, primates
Summary of Study: Study provides a detailed description of the pathogenesis of a low-passage SARS-CoV-2 isolate in two macaque species (rhesus and cynomolgus) and suggests both species represent an equally good model for COVID-19 prophylactic and therapeutic treatments.
References: doi: https://doi.org/10.1101/2020.11.05.369413
Contact Info: Ernst. J. Verschoor: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.05.369413v2
NHP Species:
Year Published:
Study Type/Review:
NPRC/Institute: Duke NUS Medical School, Singapore; Duke University Medical School
Keywords: SARS-CoV-2, lung inflammation, pathology, mice and primates
Summary of Study: Widespread degranulation of mast cells (MCs) during acute and unresolved airway inflammation in SARS-CoV-2-infected mice and non-human primates supports the association of MC activation with severe COVID-19 and suggests potential strategies for intervention.
References: PMID: 34100020 / doi: 10.1101.2021.05.31.21255594
Contact Info: Ashley St. John: [email protected]
URL: https://www.medrxiv.org/content/10.1101/2021.05.31.21255594v1
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: State Key Laboratory of Pathogen and Biosecurity, Beijing, China
Keywords: SARS-CoV-2, recombinant subunit vaccine, neutralization potency, aged animals, primates
Summary of Study: Authors developed a pilot scale pipeline producing a recombinant subunit vaccine (RBD-Fc Vacc) with Receptor Binding Domain of SARS-CoV-2S protein fused with the Fc domain of human IgG1. This vaccine induced SARS-CoV-2 specific neutralizing antibodies in non-human primates and human ACE2 transgenic mice and is currently being assessed in randomized controlled phase I/II human clinical trials.
References: doi: https://doi.org/10.1101/2020.11.29.402339
Contact Info: Yuwei Gao: [email protected]; Wenjin Wei: [email protected]; Zhonghu Hu: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.29.402339v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Shenzhen Hospital, Southern Medical University, Shenzhen, China
Keywords: SARS-CoV-2, adenovirus vectored vaccines, immunization, primates
Summary of Study: Two novel adenovirus vectored COVID-19 vaccines were produced, which, when used in succession, elicited robust humoral and T-cell immune response to SARS-CoV-2 in mice and rhesus macaques. These two vaccines are being planned for clinical phase I/II trials after an extensive safety evaluation has been carried out in pre-clinical animal examination.
References: doi: https://doi.org/10.1101/2020.09.28.311480
Contact Info: Chengyao Li: [email protected]; Tingting L: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.09.28.311480v1
NHP Species:
Year Published:
Study Type/Review:
NPRC/Institute: Inserm, CEA, Paris, France; University of Amsterdam; and others
Keywords: SARS-CoV-2, prophylactic and therapeutic effect of COVA1-18 in vivo, several species, primates
Summary of Study: COVA1-18, a neutralizing antibody isolated from a convalescent patient and highly potent against the B.1.1.7 isolate, had very strong antiviral activity in the upper respiratory compartments of cynomolgus macaques, with an estimated reduction in viral infectivity of more than 95%, and prevented lymphopenia and extensive lung lesions.
References: PMID: 33619476 / doi: 10.21203/rs.3.rs-235272/v1
Contact Info: Roger LeGrand: [email protected]; MJ Van Gils: [email protected]
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899470/pdf/nihpp-rs235272v1.pdf
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Tulane NPRC, Yerkes NPRC, New Iberia Research Center, Stanford
Keywords: SARS-CoV-2, subunit nanoparticle vaccine, primates
Summary of Study: These data reveal the promising performance of several adjuvants including AS03 and CpG 1018 (with Alum), which have been used in licensed vaccines, when used in conjunction with the SARS-CoV-2 RBD-NP immunogen.
References: PMID: 33594366 / doi: 10.1101/2021.02.10.430696
Contact Info: Bali Pulendran: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.02.10.430696v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: CAS Key Laboratory of Infection and Immunity, Beijing, China
Keywords: SARS-CoV-2, therapeutics, human monoclonal antibody, primates
Summary of Study: The authors identify and characterize a potent human monoclonal antibody, HB27, that blocks SARS-CoV-2 attachment to its cellular receptor at sub-nM concentrations. Rhesus macaques showed no obvious adverse events when they received a 10-fold effective dose. These results suggest that HB27 is a promising candidate for COVID-19 immuno-therapies.
References: doi:Â https://doi.org/10.1101/2020.11.24.393629
Contact Info: Xiangxi Wang: [email protected]; Cheng-Feng Qin: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.24.393629v1
NHP Species: rhesus macaques, pigtail macaques
Year Published:
Study Type/Review:
NPRC/Institute: National Institute of Animal Biotechnology, Telangana, India
Keywords: SARS-CoV-2, ACE2 receptor of various species, several species.
Summary of Study: The interaction of SARS-CoV-2 spike receptor-binding domain with its receptor (ACE2) in different hosts was evaluated to understand and predict viral entry. Most of the species considered in this study showed high probability of viral entry and should be followed to determine their ability to act as carriers and/or disseminators.
References: doi: https://doi.org/10.1101/2020.05.08.084327
Contact Info: Ravi Kumar Gandham: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.05.08.084327v4
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: NIAID/NIH; The Jenner Institute at the University of Oxford
Keywords: SARS-CoV-2, multiomics profiling, young and old animals, immune response, primates
Summary of Study: Despite similar disease outcomes, multi-omics profiling in SARS-CoV-2-infected rhesus macaques suggests that age may delay or impair the induction of anti-viral cellular immune responses and delay efficient return to immune homeostasis following acute infection.
References: doi: 10.1101/2021.09.08.459430
Contact Info: Emmie de Wit: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.09.08.459430v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: NIAID, Emory University, Duke University, Moderna, Bioqual
Keywords: SARS-CoV-2, mRNA vaccine, lipid nanoparticles, immune response, pathology, primates
Summary of Study: mRNA-1273 vaccine-induced antibody responses are a mechanistic correlate of protection against SARS-CoV-2 infection in NHP.
References: PMID: 33907752 / doi: 10.1101/2021.04.20.44067
Contact Info: Robert Seder: [email protected]; Barney Graham: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.04.20.440647v2
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878
Keywords: SARS-CoV-2, subunit vaccine, pulmonary disease, primates
Summary of Study: Cynomolgus macaques immunized with NVX-CoV2373 and the saponin-based Matrix-M adjuvant induced antibody that was neutralizing and blocked binding to the human angiotensin-converting enzyme 2 (hACE2) receptor. Following intranasal and intratracheal challenge with SARS-CoV-2, immunized macaques were protected against upper and lower infection and pulmonary disease.
References: doi: https://doi.org/10.1101/2020.08.18.256578
Contact Info: Gale Smith at [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.08.18.256578v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Gritstone Bio., Inc.; Battelle Biomedical Research Center
Keywords: SARS-CoV-2, prime-boost vaccination, immune response, primates
Summary of Study: Data demonstrate that the Self-amplifying mRNA (SAM) vaccine platform can drive balanced T- and B-cell responses for optimal protective immunity at low doses, offering an additional attractive vaccine platform in the fight against current and emerging infectious pathogens.
References: doi:10.1101/2021.11.08.467773
Contact Info: Karin Jooss: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.11.08.467773v1
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: ReiThera Sri, Rome, Italy; The University of Nottingham
Keywords: SARS-CoV-2, gorilla adenovirus-vectored vaccine, primates
Summary of Study: Vaccine candidate, GRAd-COV2, is highly immunogenic in both mice and cynomolgus macaques, eliciting both functional antibodies which neutralize SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and a robust, Th1-dominated cellular response in the periphery and in the lung.
References: doi: https://doi.org/10.1101/2020.10.22.349951
Contact Info: Alessandra Vitelli: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.10.22.349951v1
NHP Species:
Year Published:
Study Type/Review:
NPRC/Institute: National Institute of Infectious Diseases, Tokyo, Japan
Keywords: SARS-CoV-2, T-cell populations, primates
Summary of Study: Results suggest that the peripheral T lymphocyte population is associated with pneumonia severity in cynomolgus monkeys experimentally infected with SARS-CoV-2.
References: doi: https://doi.org/10.1101/2021.01.07.425698
Contact Info: Noriyo Nagata: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.01.07.425698v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Peking University Health Science Center, Beijing, China
Keywords: SARS-CoV-2, TLR4, trimeric spike protein binding, primates
Summary of Study: The spike protein of SARS-CoV-2 functions as a potent stimulus causing TLR4 activation and sepsis related abnormal responses.
References: doi: https://doi.org/10.1101/2020.12.18.423427
Contact Info: Xiangxi Wang: [email protected]/Fuping You: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.12.18.423427v1
NHP Species: rhesus macaques, pigtail macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: University of Washington, UNC, Chapel Hill and others
Keywords: SARS-CoV-2, multivalent receptor-binding domain nanoparticle vaccine, immune response, variants, mice and primates
Summary of Study: Mosaic and cocktail sarbecovirus RBD-NPs elicit broad and protective Ab responses against heterologous sarbecovirus challenge, which could represent the next generation of pan-sarbecovirus vaccines.
References: PMID: 33758839 / doi: 10.1101/2021.03.15.435528
Contact Info: Neil King: [email protected]; David Veesler: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.03.15.435528v1
NHP Species:
Year Published:
Study Type/Review:
NPRC/Institute: Duke University, UNC Chapel Hill, NIAID, Ragon Inst.
Keywords: SARS-CoV-2, neutralizing antibodies, cryo-electron microscopy, binding, inflammation, primates
Summary of Study: SARS-CoV-2 RBD and NTD antibodies can increase infection in vitro, but either protect or do not increase coronavirus replication in mouse and monkey models in vivo.
References: PMID: 33442694 / doi: 10.1101/2020.12.31.424729
Contact Info: Kevin Saunders: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.12.31.424729v2
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: University of Hawaii, Bioqual, Inc., Soligenix, Inc.
Keywords: SARS-CoV-2, recombinant subunit protein vaccine, spike protein, immune response, pathology, primates
Summary of Study: A recombinant subunit protein formulated with CoVaccine HT adjuvant induces superior immunity than natural infection and reduces viral load while protecting cynomolgus macaques from COVID-19-like disease caused by late SARS-CoV-2 P.1 (Gamma) challenge.
References: doi: 10.1101/2021.09.24.461759
Contact Info: Axel Lehrer: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.09.24.461759v1
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: University of Maryland School of Medicine; Noravax
Keywords: SARS-CoV-2, receptor-binding domain subunit vaccine, immune response, mice and primates
Summary of Study: Positive results in non-human primates suggest the feasibility of utilizing a B.1.351 Spike directed variant vaccine as a booster after previous immunization with a vaccine directed toward the ancestral SARS-CoV-2 Spike protein.
References: doi: 10.1101/2021.06.08.447631
Contact Info: Matthew Frieman: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.06.08.447631v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Janssen Vaccines and Prevention, The Netherlands
Keywords: SARS-CoV-2, adenovirus-vectored vaccine, neutralization potency, aged animals, primates
Summary of Study: The Janssen Ad26.COV2.S vaccine candidate is currently the only one evaluated as a single dose vaccination regimen in Phase 3 clinical studies. This study showed that a second vaccine dose (administered 8 weeks post the first immunization) induced a significant increase in antigen-specific binding and neutralizing antibody responses in both adult and aged rhesus macaques as compared to a single dose. These data support the initiation of a two-dose Ad26.COV2.S regimen in Phase 3 clinical trial in adults and elderly.
References: doi: https://doi.org/10.1101/2020.11.17.368258
Contact Info: Roland Zahn: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.17.368258v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: University of Texas Medical Branch, Galveston
Keywords: SARS-CoV-2, apoptosis in post-mortem lung, pathogenesis, primates
Summary of Study: Apoptosis was examined in post-mortem lung sections from COVID-19 patients and lung tissues from NHP models of SARS-CoV-2 infection. Multiple-target immunofluorescence assays and Western blotting suggest both intrinsic and extrinsic apoptotic pathways are activated during SARS-CoV-2 infection. These findings may help to delineate a novel insight into the pathogenesis of ARDS following SARS-CoV-2 infection.
References: PMID: 33398280/doi: 10.1101/2020.12.23.424254
Contact Info: Bin Gong: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.12.23.424254v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Yerkes NPRC, NIH, Ragon Institute, and others
Keywords: SARS-CoV-2, adjuvanted soluble protein vaccines, binding and functional neutralization assays and systems serology, primates
Summary of Study: Potent serum antibody responses are induced by soluble S trimers formulated with the oil-in-water emulsion adjuvant AS03, which conferred protection in the upper and lower airways of rhesus macaques following SARS-CoV-2 challenge.
References: PMID: 33688652 / doi: 10.1101/2021.03.02.433390
Contact Info: Robert Seder: [email protected]
URL: https://pubmed.ncbi.nlm.nih.gov/33688652/
NHP Species: african green monkeys
Year Published:
Study Type/Review: vaccine
NPRC/Institute: City of Hope National Medical Center; Bioqual
Keywords: SARS-CoV-2, vaccine efficacy, humoral and cellular immune responses, primates
Summary of Study: COH04S1, a synthetic multiantigen Modified Vaccinia Ankara-based SARS-CoV-2 vaccine that co-expresses spike and nucleocapsid antigens, demonstrated protection in animal models through different vaccination routes and dose regimens, complementing ongoing investigation of this multiantigen SARS-CoV-2 vaccine in clinical trials.
References: PMID: 34545366 / doi: 10.1101/2021.09.15.460487
Contact Info: Felix Wussow: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.09.15.460487v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Inovio Pharmaceuticals; The Wistar Institute
Keywords: SARS-CoV-2, DNA vaccine candidate, immunogenicity, boost, primates
Summary of Study: Data illustrate the durability of immunity following vaccination with synthetic DNA vaccine candidates INO-4800 or INP-4802 and additional support the use of either INO-4800 or INP-4802 in prime-boost regimens.
References: doi: 10.1101/2021.10.27.466163
Contact Info: Kate Broderick: [email protected]; David Weiner: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.10.27.466163v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Clover Biopharmaceuticals, Chengdu, China
Keywords: SARS-CoV-2, Trimer-Tag technology, neutralizing antibodies, primates
Summary of Study: Rhesus macaques immunized with adjuvanted S-Trimer were protected from SARS-CoV-2 challenge compared to vehicle controls. Trimer-Tag may be an important new platform technology for scalable production and rapid development of safe and effective subunit vaccines against current and future emerging RNA viruses.
References: doi: https://doi.org/10.1101/2020.09.24.311027
Contact Info: Pen Liang: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.09.24.311027v1
NHP Species: pigtail macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Nanogen Pharmaceutical Biotechnology JSC
Keywords: SARS-CoV-2, vaccine candidate, receptor-binding domain, immune response, hamsters, mice, primates
Summary of Study: Nanocovax, a vaccine candidate based on recombinant protein production of the extracellular (soluble) portion of the S protein of SARS-CoV-2, induced high levels of S protein-specific IgG, as well as neutralizing antibody in three animal models (mice, Syrian hamsters, and Macaca leonina (Northern pig-tailed macaque).
References: doi: 10.1101/2021.07.20.453162
Contact Info: Do Minh Si: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.07.20.453162v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Ragon Institute of MGH, MIT and Harvard
Keywords: SARS-CoV-2, humoral immune response, recombinant full-length spike glycoprotein (NVX-CoV2373), primates
Summary of Study: Deep profiling of the humoral immune response in a cohort of non-human primates immunized with one or two doses of 5 or 25 ug of a stabilized recombinant full-length SARS-CoV-2 spike glycoprotein with 50 ug Matrix-M adjuvant suggests that a single dose of may prevent disease, but that two doses may be essential to block further transmission of SARS-CoV-2 and emerging variants.
References: PMID: 33619473 / doi: 10.21203/rs.3.rs-200342/v1
Contact Info: Galit Alter: [email protected]
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899467/pdf/nihpp-rs200342v1.pdf
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Fred Hutchinson Cancer Research Center
Keywords: SARS-CoV-2, Remdesivir, mathematical models, primates
Summary of Study: Developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaque
References: doi: https://doi.org/10.1101/2020.06.21.163550
Contact Info: Joshua Schiffer, [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.06.21.163550v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Oyster Point Pharma; Trudeau Institute
Keywords: SARS-CoV-2, varenicline tartrate, in vitro and in vivo studies, virus infection, primates
Summary of Study: The nAChR agonist varenicline has the potential to interact with and inhibit SARS-CoV-2 infection and replication.
References: doi: 10.1101/2021.06.29.450426
Contact Info: Jeffrey Nau: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.06.29.450426v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: ImmunityBio, NantK west, Inc., IosBio
Keywords: SARS-CoV-2, hAd5 S-Fusion + N-ETSD vaccine, efficacy, primates
Summary of Study: NHP immunized with the hAd5 S-Fusion + N-ETSD vaccine generated anti-S IgG and showed inhibition in cPass and thus the presence of anti-S RBD neutralizing antibodies (nAbs).
References: doi: 10.1101/2020.12.08.416297
Contact Info: Patrick Soon-Shiong: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.12.08.416297v1
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Duke University, NIAID, 3 M Company
Keywords: SARS-CoV-2, receptor binding domain nanoparticle, vaccination, immune response, primates
Summary of Study: An RBD-scNP vaccine induced robust protective immunity for SARS-CoV-2 replication in the upper and lower respiratory tract. This vaccine represents a platform for producing a pancoronavirus vaccine that could prevent, rapidly temper, or extinguish the next spillover of a coronavirus into humans.
References: doi: 10.1101/2021.02.17.431492
Contact Info: Kevin Saunders: [email protected]; Barton Haynes: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.02.17.431492v1
NHP Species:
Year Published:
Study Type/Review:
NPRC/Institute: Duke University School of Medicine
Keywords: SARS-CoV-2, neutralizing and infection-enhancing antibodies, mice and primates
Summary of Study: SARS-CoV-2 antibodies can mediate infection enhancement in vitro. However, this in vitro phenotype does not translate to enhanced infection in a non-human primate model of SARS-CoV-2 infection. These preclinical results indicate that SARS-CoV-2 antibody treatments or the induction of SARS-CoV-2 antibodies by vaccination have a low likelihood of exacerbating COVID-19 disease in humans.
References: doi: https://doi.org/10.1101/2020.12.31.424729
Contact Info: Barton Haynes: [email protected]/Kevin Saunders: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.12.31.424729v2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: NIAID, Emory University, Moderna
Keywords: SARS-CoV-2, mRNA vaccine, immune response, pathology, primates
Summary of Study: Immunization with two doses of mRNA-1273 achieves effective immunity that rapidly controls lower and upper airway viral replication against the B.1.351 variant in NHP.
References: doi: 10.1101/2021.05.21.445189
Contact Info: Barney Graham: [email protected]; Robert Seder: [email protected];
URL: https://www.biorxiv.org/content/10.1101/2021.05.21.445189v1
NHP Species: african green monkeys
Year Published:
Study Type/Review:
NPRC/Institute: University of TX Medical Branch
Keywords: SARS-CoV-2, convalescent sera, primates, viral load and disease pathology
Summary of Study: Groups of SARS-CoV-2 infected AGMs were treated with pooled convalescent sera containing either high or low to moderate anti-SARS-CoV-2 neutralizing antibody titers. Lower levels of SARS-CoV-2 in respiratory compartments, reduced gross and histopathological lesion severity in the lungs, and reductions in several parameters associated with coagulation and inflammatory processes were observed in monkeys that received convalescent sera versus untreated controls.
References: doi: https://doi.org/10.1101/2020.10.14.340091
Contact Info: Thomas Geisbert: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.10.14.340091v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: CureVac AG Tuebingen, Germany
Keywords: SARS-CoV-2, mRNA vaccine CVnCoV, safety, immunogenicity, and protective efficacy, primates
Summary of Study: The efficacy of CVnCoV, a lipid-nanoparticle encapsulated, sequence optimized mRNA-based SARS-CoV-2 vaccine was evaluated. The study demonstrates that CVnCoV induces robust humoral and cellular responses in non-human primates. These results demonstrate safety, immunogenicity, and protective efficacy of this vaccine that extend beyond previously published preclinical data and provide strong support for further clinical testing in ongoing phase 2b/3 efficacy studies.
References: doi: https://doi.org/10.1101/2020.12.23.424138
Contact Info: no contact information provided
URL: https://www.biorxiv.org/content/10.1101/2020.12.23.424138v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: ImmunityBio, Culver City, CA
Keywords: SARS-CoV-2, prime and oral boost bivalent hAd5 vaccination, T-cell response, primates
Summary of Study: Treatment with bivalent hAd5S-Fusion + N-ETSD subcutaneous and oral vaccine provided complete protection of nasal and lung airways against SARS-CoV-2 challenge in rhesus macaques. Data demonstrate that all NHPs immunized with the hAD5 S-Fusion + N-ETSD vaccine generated anti-S IgG and that 9 of 10 animals showed inhibition in cPass (TM) and thus the presence of anti-S RBD neutralizing antibodies.
References: doi: https://doi.org/10.1101/2020.12.08.416297
Contact Info: Patrick Soon-Shiong: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.12.08.416297v3
NHP Species: multiple species
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Duke Human Vaccine Institute
Keywords: SARS-CoV-2, multimeric receptor binding domain nanoparticle, cross-neutralizing antibody, virus variants, primates
Summary of Study: This study demonstrates the ability of a SARS-CoV-2 RBD 24-mer subunit nanoparticle vaccine to elicit potent cross-neutralizing antibodies against SARS-CoV-1, SARS-CoV-2, SARS-CoV-2 variant B.1.1.7. as well as SARS-related bat betaCoVs.
References: PMID: 33619494 / doi: 10.1101/2021.02.17.431492
Contact Info: Kevin Saunders: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.02.17.431492v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Chinese Academy of Sciences
Keywords: SARS-CoV-2, interferon (IFN)-armed receptor-binding domain, immune response, primates
Summary of Study: The pan-epitope modified human I-R-F (I-P-R-F) vaccine provides rapid and complete protection throughout the upper and lower respiratory tracts against a high-dose SARS-CoV-2 challenge in rhesus macaques.
References: doi: 10.1038/s41422-021-00531-8
Contact Info: Hua Peng: https://www.nature.com/articles/s41422-021-00531-8/email/correspondent/c3/new
URL: https://www.nature.com/articles/s41422-021-00531-8
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: University of Pennsylvania
Keywords: SARS-CoV-2, vaccine, pseudovirus, neutralizing antibodies, mice, primates, humans
Summary of Study: SARs-CoV-2 recently mutated near the region targeted by many vaccines. The current study tested whether the mutation would hinder the ability of current vaccines to induce neutralizing antibodies in mice/NHPs/human serum. Their results indicate the viral mutation will not interfere with the effects of vaccines developed based on the original protein structure.
References: doi: 10.1101/2020.07.22.20159905
Contact Info: Drew Weissman, Email: [email protected] OR Davis Montefiori, email: [email protected]
URL: https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: BioNTech, Mainz, Germany
Keywords: SARS-CoV-2, BNT162b vaccine, primates
Summary of Study: Prime/boost vaccination of rhesus macaques with BNT162b candidates protect macaques from SARS-CoV-2 challenge. Both candidates are being evaluated in phase 1 trials in Germany and the US.
References: doi: https://doi.org/10.1101/2020.12.11.421008
Contact Info: Ugur Sahin: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.12.11.421008v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: NIAID, Emory University
Keywords: SARS-CoV-2, mRNA vaccine, virus genome variants, immune response, pathology, primates
Summary of Study: Immunization with two doses of mRNA-1273 achieves effective immunity that rapidly controls lower and upper airway viral replication against the B-1.351 variant in NHP.
References: PMID: 34075375 / doi: 10.1101/2021.05.21.445189
Contact Info: Barney Graham: [email protected]; Robert Seder: [email protected];
URL: https://www.biorxiv.org/content/10.1101/2021.05.21.445189v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Eli Lilly & Co.; NIAID
Keywords: SARS-CoV-2, anti-spike neutralizing antibodies, primate challenge model
Summary of Study: Prophylactic treatment with LY-CoV555 (a neutralizing antibody) resulted in significant decreases in viral load (gRNA) and viral replication (sgRNA) in the lower respiratory tract of rhesus macaques following SARS-CoV2 inoculation, based on determination in BAL and lung tissue.
References: doi:Â https://doi.org/10.1101/2020.09.30.318972
Contact Info: Bryan Jones: [email protected]; Ester Falconer: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.09.30.318972v3
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: Harvard Medical School
Keywords: SARS-CoV-2, Multiplexed proteomics and imaging, acute respiratory distress, primates
Summary of Study: The data in this paper highlight the ability of proteomics, imaging, and spatial transcriptomics of the same specimens to trace successive steps in diverse regulatory cascades. This approach is applicable to any fixed tissue. No other approach involving readily available histological specimens provides a similarly integrated picture of a disease process.
References: doi: https://doi.org/10.1101/2020.10.14.339952
Contact Info: Marian Kalocsay: [email protected]; Peter Sorger: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.10.14.339952v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Harvard Medical School
Keywords: SARS-CoV-2, AAV-based, single dose vaccine, primates
Summary of Study: Two adeno-associated viral (AAV)-based vaccine candidates demonstrate potent immunogenicity in mouse and NHP models following a single injection. Moreover, the vaccine is stable at room temperature for a least one month and is produced at high yields using established commercial manufacturing processes in the gene therapy industry.
References: doi: https://doi.org/10.1101/2021.01.05.422952
Contact Info: Luk Vandenberghe: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.01.05.422952v3
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Intuitive Biosciences
Keywords: SARS-CoV-2, spike binding antibodies with neutralizing activity, immunization, primates
Summary of Study: Efficacy of vaccine candidates based on the SARS-CoV-2 spike was assessed in cynomolgus macaques by examining their ability to generate spike binding antibodies with neutralizing activity. Neutralizing activity persisted for more than 20 weeks. These data support the utility of spike subunit-based antigens as a vaccine for use in humans.
References: PMID: 33398285/doi: 10.1101/2020.12.20.422693
Contact Info: Kimberly Luke (no contact information)
URL: https://www.biorxiv.org/content/10.1101/2020.12.20.422693v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review: vaccine
NPRC/Institute: University of Oxford
Keywords: SARS-CoV-2, protein nanoparticle vaccine, primates
Summary of Study: Ferrets and rhesus macaques were challenged with SARCS-CoV-2 to assess the potential for vaccine-enhanced disease (VED) in animals vaccinated with formaldehyde-inactivated SARS-CoV-2 formulated with Alhydrogel. This study revealed no evidence of enhanced disease in rhesus macaques.
References: doi: https://doi.org/10.1101/2020.12.21.423746
Contact Info: Andrew Gorringe: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.12.21.423746v1
NHP Species:
Year Published:
Study Type/Review: vaccine
NPRC/Institute: Sanofi Pasteur, GSK
Keywords: SARS-CoV-2, virus genomic variants, vaccine boosters, immune response, primates
Summary of Study: One booster dose of AS03-adjuvanted CoV2 preS dTM, D614 (parental) or B.1.351 (Beta), in monovalent of bivalent formulations, significantly booster pre-existing neutralizing antibodies and elicited high and stable cross-neutralizing antibodies covering the four known SARS-CV-2 variants of concern.
References: doi: 10.1101/2021.09.20.461023
Contact Info: Valerie Lecouturier: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2021.09.20.461023v1
NHP Species: rhesus macaques
Year Published:
Study Type/Review:
NPRC/Institute: University of Bern
Keywords: SARS-CoV-2, airway epithelial cell (AEC) culture repository, multiple animal species
Summary of Study: Well-differentiated primary airway epithelial cell cultures were established from various domestic and wildlife animal species (including rhesus macaques) to assess the potential intermediate and spillback host reservoir spectrum of SARS-CoV-2. rhesus macaque post-mortem tracheobronchial airway tissue material. These were inoculated with SARS-CoV-2/Munchen-1.1/2020/929 isolate and monitored for viral titer for 96 hours. Infectious progeny virus were absent in most species, except rhesus macaques and cats, indicating that some species are not ideally suited as animal models in studies of SARS-CoV-2.
References: doi: https://doi.org/10.1101/2020.11.10.374587
Contact Info: Ronald Dijkman: [email protected]
URL: https://www.biorxiv.org/content/10.1101/2020.11.10.374587v1

